Skip to content

The safety, immunogenicity of inactivated COVID-19 vaccine in adult rheumatoid patients: a prospective cohort study

The safety, immunogenicity of inactivated COVID-19 vaccine in adult rheumatoid patients: a prospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049114
Enrollment
Unknown
Registered
2021-07-21
Start date
2021-07-18
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Post-marketing vaccination of COVID-19 vaccine

Sponsors

Shenzhen Futian Hospital for Rheumatic Diseases
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.The subjects were Chinese adults diagnosed with rheumatism; 2.Aged 18 to 60 years; 3.Patients know their diagnosis clearly; 4.Have basic reading and comprehension skills; 5.Cognitive ability, mental disorders, etc.

Exclusion criteria

Exclusion criteria: Researchers believe that other reasons are not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
Novel Coronavirus neutralizing antibody;

Secondary

MeasureTime frame
Adverse reactions;

Countries

China

Contacts

Public ContactZeng Huiqiong

Shenzhen Futian Hospital for Rheumatic Diseases

zenghuiqiong0529@163.com+86 15986686048

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026